Skip to main content
. 2022 Sep 6;12(15):6437–6445. doi: 10.7150/thno.77219

Figure 1.

Figure 1

A 45-year-old man with metastatic pancreatic neuroendocrine tumor (G1; Ki-67, 1%). The baseline 68Ga-DOTATATE PET/CT (A, MIP image; B, fused PET/CT) showed somatostatin receptor expression in liver metastases. The patient was treated with 3 cycles of 177Lu-DOTA-EB-TATE with cumulative administered activity of 12.4 GBq. Two months post-therapy 68Ga-DOTATATE PET/CT (C, MIP image; D, fused PET/CT) showed partial response. 68Ga-DOTATATE PET/CT at 3-year follow-up showed stable disease (E, MIP image; F, fused PET/CT) with progression-free survival of 43 months from the first cycle of 177Lu-DOTA-EB-TATE PRRT.